Nkarta said it will present first human data for its NK-cell therapy across two autoimmune indications—myositis and systemic sclerosis—highlighting safety and early signs of activity. The company’s upcoming disclosure is positioned as a key early validation point for an expanding class of immune-resetting approaches. The update matters because autoimmune cell therapies often face tight early safety constraints while requiring credible functional engagement of target immune pathways. Nkarta is betting that natural killer-cell biology can modulate dysregulated immune circuits without broad systemic immunosuppression. Investors and clinicians will focus on dose levels, adverse-event patterns, and any signal of clinical meaningfulness as the program progresses beyond initial cohorts.